北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance
作者: Jiang, Qian; Qin, Ya-Zhen; Lai, Yue-Yun; Jiang, Hao; Wang, Jing; Huang, Xiao-Jun
关键词: BCR-ABL ; mutation ; chronic myeloid leukemia ; dasatinib ; nilotinib ; imatinib
刊名: LEUKEMIA & LYMPHOMA
发表日期: 2015-07-01
DOI: 10.3109/10428194.2014.982639
卷: 56, 期:7, 页:2075-2081
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: CHRONIC MYELOID-LEUKEMIA ; ABL KINASE DOMAIN ; CHRONIC MYELOGENOUS LEUKEMIA ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; NILOTINIB FORMERLY AMN107 ; GIMEMA WORKING PARTY ; IMATINIB-RESISTANT ; CHRONIC-PHASE ; ACCELERATED-PHASE ; BLAST CRISIS
英文摘要:

The treatment outcome and development of new mutations in patients with imatinib- and/or nilotinib-failure Philadelphia chromosome positive (Ph+) leukemia with highly nilotinib-resistant mutations (Y253H, E255K/V and F359V/C) were assessed on dasatinib therapy. A total of 111 patients with Ph+ leukemia were grouped into three cohorts by baseline BCR-ABL kinase domain mutation status: no mutation (n = 44), non-nilotinib-resistant mutations (n = 26) or nilotinib-resistant mutations (n = 41). The frequencies of hematological, cytogenetic and molecular responses and clinical resistance to dasatinib were similar among the three cohorts during dasatinib therapy. In dasatinib-resistant patients, new mutations were most frequently observed in the cohort with nilotinib-resistant mutations (p = 0.001). Multivariate analysis revealed that advanced disease and harboring Y253H or F359V mutation before dasatinib were independent predictors of developing new mutations. We conclude that patients with Ph+ leukemia with Y253H or F359V mutation have a high likelihood of developing new mutations in the setting of dasatinib resistance.

语种: 英语
所属项目编号: Z131100004013026
项目资助者: Beijing Municipal Science &amp ; Technology Commission
WOS记录号: WOS:000359888700025
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58495
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China

Recommended Citation:
Jiang, Qian,Qin, Ya-Zhen,Lai, Yue-Yun,et al. Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance[J]. LEUKEMIA & LYMPHOMA,2015,56(7):2075-2081.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jiang, Qian]'s Articles
[Qin, Ya-Zhen]'s Articles
[Lai, Yue-Yun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jiang, Qian]‘s Articles
[Qin, Ya-Zhen]‘s Articles
[Lai, Yue-Yun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace